Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ)
CNY 12.29
(-0.32%)
CNY 12.29
(-0.32%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 2.61 Billion | 2.67 Billion | 2.42 Billion | 1.89 Billion | 2.53 Billion | 2.36 Billion |
| Cost of Revenue | 1.08 Billion | 940.48 Million | 806.55 Million | 657.14 Million | 917.45 Million | 903.94 Million |
| Gross Profit | 1.52 Billion | 1.73 Billion | 1.62 Billion | 1.23 Billion | 1.61 Billion | 1.45 Billion |
| Operating Expenses | 1.23 Billion | 1.34 Billion | 1.22 Billion | 957.8 Million | 1.13 Billion | 940.32 Million |
| Selling, General and Administrative Expenses | 1.04 Billion | 1.04 Billion | 998.72 Million | 772.79 Million | 910.26 Million | 797.03 Million |
| Research and Development Expenses | 133.26 Million | 156.59 Million | 136.72 Million | 113.62 Million | 132.58 Million | 84.29 Million |
| Other Expenses | 197.18 Million | 142.68 Million | 86.71 Million | 71.38 Million | 88.99 Million | -986.95 Thousand |
| Cost and Expenses | 2.31 Billion | 2.28 Billion | 2.02 Billion | 1.61 Billion | 2.04 Billion | 1.84 Billion |
| Operating Income | 346.2 Million | 374.26 Million | 443.32 Million | 388 Million | 518.91 Million | 500.95 Million |
| Interest Expense | 46.91 Million | 73.35 Million | 73.81 Million | 37.2 Million | 48.21 Million | 34.04 Million |
| Income Tax Expense | 33.75 Million | 52.95 Million | 34.8 Million | 89.15 Million | 59.1 Million | 69.46 Million |
| Earnings before Tax | 283.65 Million | 368.3 Million | 309.47 Million | -345.27 Million | 378.87 Million | 499.96 Million |
| Net Income | 263.27 Million | 322.05 Million | 277.63 Million | -434.42 Million | 317.72 Million | 435.64 Million |
| Earnings Per Share Basic | 0.32 | 0.40 | 0.35 | -0.54 | 0.40 | 0.54 |
| Earnings Per Share Diluted | 0.32 | 0.40 | 0.35 | -0.54 | 0.40 | 0.53 |
| Weighted Average Shares Outstanding | 822.72 Million | 805.12 Million | 797.43 Million | 803.35 Million | 803.35 Million | 806.75 Million |
| Weighted Average Shares Outstanding (Diluted) | 822.72 Million | 805.12 Million | 797.43 Million | 803.35 Million | 803.35 Million | 821.97 Million |
| Gross Margin | 0.59 | 0.65 | 0.67 | 0.65 | 0.64 | 0.62 |
| EBIT Margin | 0.17 | 0.20 | 0.22 | 0.26 | 0.24 | 0.27 |
| Profit Margin | 0.10 | 0.12 | 0.11 | -0.23 | 0.13 | 0.18 |
| EBITDA | 453.78 Million | 542.79 Million | 479.3 Million | -207.01 Million | 525.38 Million | 611.47 Million |
| Earnings Before Tax Margin | 0.13 | 0.14 | 0.18 | 0.20 | 0.20 | 0.21 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 543.65 Million | 723.24 Million | 641.12 Million | 2.61 Billion | 539.27 Million | 588.98 Million |
| Cost of Revenue | 250.24 Million | 308.74 Million | 278.95 Million | 1.08 Billion | 260.41 Million | 252.6 Million |
| Gross Profit | 293.41 Million | 414.49 Million | 362.17 Million | 1.52 Billion | 278.85 Million | 336.38 Million |
| Operating Expenses | 270.25 Million | 295.87 Million | 280.29 Million | 1.17 Billion | 280.04 Million | 252.15 Million |
| Selling, General and Administrative Expenses | 309.87 Million | 215.08 Million | 246.61 Million | - | 129.02 Million | 282.14 Million |
| Research and Development Expenses | 28.63 Million | 27.48 Million | 29.97 Million | - | 46.24 Million | 27.66 Million |
| Other Expenses | -68.24 Million | -57.8 Million | -157.26 Thousand | -15.07 Million | -13.54 Million | -217.54 Thousand |
| Cost and Expenses | 520.5 Million | 604.62 Million | 559.25 Million | 2.25 Billion | 540.46 Million | 504.76 Million |
| Operating Income | 78.76 Million | 98.29 Million | 59.27 Million | 298.73 Million | -17.15 Million | 81.22 Million |
| Interest Expense | 7.11 Million | 7.6 Million | 8.52 Million | 46.91 Million | 11.61 Million | 11.91 Million |
| Income Tax Expense | 21.03 Million | 10.36 Million | 10.4 Million | 33.75 Million | -1.38 Million | 14.04 Million |
| Earnings before Tax | 78.11 Million | 40.49 Million | 59.11 Million | 283.65 Million | -30.7 Million | 81 Million |
| Net Income | 61.39 Million | 36.11 Million | 51.29 Million | 263.27 Million | -16.22 Million | 70.94 Million |
| Earnings Per Share Basic | 0.08 | 0.04 | 0.06 | - | -0.02 | 0.08 |
| Earnings Per Share Diluted | 0.08 | 0.04 | 0.06 | - | -0.02 | 0.08 |
| Weighted Average Shares Outstanding | 767.4 Million | 853.35 Million | 854.89 Million | 822.72 Million | 824.77 Million | 861.9 Million |
| Weighted Average Shares Outstanding (Diluted) | 767.4 Million | 853.35 Million | 854.89 Million | 822.72 Million | 824.77 Million | 861.9 Million |
| Gross Margin | 0.54 | 0.57 | 0.56 | 0.59 | 0.52 | 0.57 |
| EBIT Margin | 0.16 | 0.10 | 0.15 | - | 0.01 | 0.16 |
| Profit Margin | 0.11 | 0.05 | 0.08 | 0.10 | -0.03 | 0.12 |
| EBITDA | 85.23 Million | 75.82 Million | 95.17 Million | - | 3.85 Million | 96.48 Million |
| Earnings Before Tax Margin | 0.14 | 0.14 | 0.09 | 0.11 | -0.03 | 0.14 |
AGGI
CMOPF
007280
KP2
UNITEDTE
IVITF